<DOC>
	<DOCNO>NCT00706810</DOCNO>
	<brief_summary>Meningiomas account 20 % primary adult brain tumor , occur annual incidence 6 per 100,000 ( Louis , Scheithauer et al . 2000 ) . Complete surgical resection treatment choice may possible tumor invades critical structure ( e.g. , skull base , sagittal sinus ) ( Mirimanoff , Dosoretz et al . 1985 ; al-Rodhan Laws 1990 ; Al-Rodhan Laws 1991 ; Newman 1994 ; De Monte 1995 ; Levine , Buchanan et al . 1999 ; Barnett , Suh et al . 2000 ; Ragel Jensen 2003 ) . Up 20 % meningiomas exhibit aggressive phenotype respond standard therapy ( Kyritsis 1996 ) . Adjuvant therapy critical patient subset meningioma . Radiation therapy stereotactic radiosurgery good adjuvant therapy limit radiation neurotoxicity , tumor size constraint , injury adjacent vascular structure cranial nerve ( Goldsmith , Wara et al . 1994 ; Barnett , Suh et al . 2000 ; Goldsmith Larson 2000 ) . Standard chemotherapeutic treatment disappoint ( Kyritsis 1996 ) . Even drug like temozolomide show efficacy malignant brain tumor fail inhibit growth refractory meningioma phase II study ( Chamberlain , Tsao-Wei et al . 2004 ) .</brief_summary>
	<brief_title>Combination Hydroxyurea Verapamil Refractory Meningiomas</brief_title>
	<detailed_description>The investigator demonstrate previously calcium channel antagonist ( CCAs ) verapamil , nifedipine , diltiazem block vitro vivo meningioma growth clinically relevant dos ( Jensen , Lee et al . 1995 ; Jensen , Petr et al . 2000 ; Jensen Wurster 2001 ) . However , modest growth inhibition exhibit tumor study CCAs alone . Many author show augmented growth inhibition add CCAs traditional chemotherapy tumor type ( Tsuruo , Iida et al . 1981 ; Tsuruo , Iida et al . 1983 ; Helson 1984 ; Robinson , Clutterbuck et al . 1985 ; Ince , Appleton et al . 1986 ; Merry , Fetherston et al . 1986 ; Cano-Gauci Riordan 1987 ) . For instance , combination verapamil 1,3-bis ( 2-chloroethyl ) -1-nitrosourea ( BCNU ) good BCNU alone inhibit growth human glioma vitro vivo ( Bowles , Pantazis et al . 1990 ) . Calcium antagonists seem exert majority anti-tumor effect inhibit calcium dependent secondary messenger system ( Metcalfe , 1986 # 74 ; Jensen , 2000 # 15 ) . Furthermore , investigator recently demonstrate addition verapamil diltiazem HU enhance growth inhibition see drug vitro vivo . Hydroxyurea inhibit DNA synthesis inhibition ribonucleotide diphosphate reductase well-known drug use treatment number tumor type include head neck tumor chronic myelogenous leukemia . It also use adjuvant antiretroviral treatment patient HIV treatment polycythemia vera , essential thrombocythemia sickle cell disease . Hydroxyurea well absorbed oral administration peak serum concentration achieve two hour . The drug excrete primarily urine , either urea unchanged compound . The drug supply 500 mg capsule white crystalline powder . It store room temperature . Dosing usually range 20 mg/kg/day adjustment necessary patient renal insufficiency . In current study population patient would usually treat 500mg twice day . It contraindicate patient myelosuppression severe anemia . Verapamil another commonly use medication . It use treatment angina , hypertension , supraventricular arrhythmia , migraine prophylaxis . Dosing standard verapamil 80-120 mg pox three time day sustain release form give 120-480mg twice day . It contraindicate patient leave ventricular dysfunction , congestive hart failure , hypotension ( systolic &lt; 90bpm ) 2nd 3rd degree atrioventricular block ( except patient function artificial pacemaker ) , sick sinus syndrome atrial flutter atrial fibrillation accessory bypass tract ( Wolff-Parkinson-White Syndrome , Lown-Ganong-Levine Syndrome ) . Serious adverse reaction associate Verapamil use congestive heart failure , hypotension , bradycardia , 2nd 3rd degree AC block , angina , myocardial infarction , syncope GI obstruction . STUDY PROCEDURES : Screening pretreatment assessment : Written inform consent obtain study-specific screening evaluation perform . After receive subject 's agreement participate study verify subject meet eligibility criterion , follow perform : Medical surgical history , prior cancer therapy ( include prior chemotherapy radiation therapy ) , complete physical examination , orthostatic vital sign , blood pressure , heart rate , temperature , weight , height , Karnofsky performance status ( See appendix ) , neurological evaluation , current medication , drug allergy . The following laboratory evaluation obtain : complete blood count ( include differential , hemoglobin , platelet count ) , serum chemistry ( BUN , creatine , sodium , potassium , bicarbonate , chloride , calcium , glucose , LDH , total protein , total bilirubin , ALT , AST , alkaline phosphatase , albumin ) , serum pregnancy test ( woman childbearing age , woman - documentation medical history confirm subject childbearing potential ) . All subject undergo ECG test screening . Patients incomplete bundle branch first degree AV conduction problem n't exclude study monitor serial monthly ECG exams frequently symptoms occur . All subject undergo MRI brain ( CT contrast unable MRI ) without Gadolinium contrast ass tumor measurement within three four week prior begin treatment . Patients also undergo Positron Emission Tomography ( PET ) metabolic FDG ( radiopharmaceutical fluorodeoxyglucose ) marker assess tumor activity . Baseline FDG/PET scan give enrol patient screen every 6 month , thereafter . Assessments treatment phase : Patients receive oral hydroxyurea twice daily 2 year absence disease progression unacceptable toxicity . Responders may continue beyond 2 year protocol treatment discretion physician . If therapy stop reason , therapy may reinstituted discontinuance exceed 4 consecutive week . The dose 20 mg/kg/day divide twice daily dos . The calculated dose round near multiple 500 mg . Patients typically receive either 1,000 mg/day 1,500 mg/day . If dose 1,500 mg/day , divide 500 mg po every morning 1,000 mg po . bedtime . Verapamil sustain release tablet begin dose 120 mg day two week , 240 mg day two week , 360 mg day two week , 240 mg twice day . If baseline SBP &lt; 110 mmHg initial Verapamil sustain release dose 60 mg ( 1/2 120 mg tablet ) day two week . Patients blood pressure heart rate measurement do weekly first month monthly thereafter . Other clinical laboratory evaluation perform 1 month interval include : limited physical examination , orthostatic vital sign , blood pressure , heart rate , temperature , Karnofsky performance status , neurologic evaluation , serum chemistry ( BUN , creatine , sodium , potassium , bicarbonate , chloride , calcium , glucose , LDH , total protein , total bilirubin , ALT , AST , alkaline phosphatase , albumin ) . Concomitant medication adverse event also collect . Complete blood count ( include differential , hemoglobin , platelet count ) , do weekly throughout study count stabilize two month , labs do every two week thereafter closely monitor side-effect myelosuppression . Patients incomplete bundle branch first degree AV conduction abnormality n't exclude study monitor monthly ECG exams frequently symptoms occur . Subjects undergo MRI gadolinium ( CT contrast unable MRI ) every three month begin treatment . Measurements make image slice large cross sectional area . Two orthogonal measure make determine maximal AP lateral dimension . PET image do baseline every 6 month proliferative metabolic activity compare baseline image . Tumor location tumor size obtain CT/MRI . Treatment response clinical progression frequently difficult measure directly . Serial neurological exam , CT/MRI PET scan may provide guide actual course response progression . Deterioration neurological status tumor regrowth CT/MRI PET must sustain time declare clinical progression . The time interval progression measure day last CT/MRI treatment every 3-4 month deterioration document . The patient consistently follow diagnostic imaging study formal evaluation radiological tumor progression tumor response do post study Patients treat two year study . Progression disease define great 25 % increase large cross sectional area two orthogonal measurement . Patients discontinue illness prevents treatment include unacceptable toxicity ( Grade 3 4 fails resolve dose medication per protocol ) study drug .</detailed_description>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>1 . Must age &gt; 18 year 2 . Patient able provide write informed consent 3 . Histologically confirm meningioma WHO grade ( write pathology report surgery require ) 4 . Radiographic demonstration least 25 % increase tumor cross sectional area measure CT/MRI within last 6 month 5 . Patients refuse surgical radiation therapy option 6 . WBC least 2,500/mm3 7 . Platelet count least 100,000/mm3 8 . Hemoglobin &gt; 8.0 g/dL 9 . Renal insufficiency ( glomerular filtration rate ( GFR ) &lt; 60 estimate CockcroftGault equation ) ineligible 10 . Hepatic disease ( ALT , AST , bilirubin , alkaline phosphatase &gt; 3 time upper limit normal ) know cirrhosis ineligible 11 . Clinically significant cardiovascular disease specifically patient follow condition ineligible : congestive heart failure know bundle branch AV conduction problem 2nd 3rd degree atrioventricular block ( except patient artificial pacemaker ) , sick sinus syndrome atrial flutter atrial fibrillation accessory bypass tract ( WolffParkinsonWhite Syndrome , LownGanongLevine Syndrome ) , history myocardial infarction past 6 month currently take betablockers , digoxin , neuromuscular block agent Bradycardia ( rest heart rate &lt; 60 beat per minute ) 12 . Hypotension ( rest blood pressure &lt; 90 systolic ) 13 . Altered neuromuscular transmission ( Duchenne Muscular Dystrophy , myasthenia gravis ) 14 . Karnofsky performance score 50100 % 15 . Life expectancy 6 month 16 . Pregnant nursing female ineligible . Fertile patient must use effective contraception 17 . Received prior investigational agent past 6 month ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Brain cancer</keyword>
	<keyword>Meningioma</keyword>
</DOC>